Navigation Links
Defensins Ward Off HIV In Two Ways

The body attempts to protect itself from HIV infection via the innate immune system. Defensins are proteins found in cells, which have been shown to have anti-HIV activity. However, the mechanism by which the defensins control HIV infection has not been known. Appearing online on February 17 in advance of publication in the March 1 print edition of the Journal of Clinical Investigation, Theresa Chang and colleagues from Mount Sinai School of Medicine analyze how alpha-defensin-1, in particular, inhibits HIV infection in CD4+ T cells. CD4 + T cells are white blood cells that have molecules called CD4 on their exterior. They help orchestrate the body's response to viruses and therefore play important roles in the immune system.

The researchers show that alpha-defensin-1 fights HIV in two different ways. Without serum (the watery portion of blood that remains when blood cells are removed) and under conditions where viral burden is low, alpha-defensin-1 directly inactivates HIV virus. When serum is present, alpha-defensin-1 acts on vulnerable cells to block HIV infection at the stage when the virus is taken up by the cell and begins replicating itself and integrating into the host. The authors also show that the way alpha-defensin-1 blocks HIV infection in cells is by inhibiting a CD4+ cell-signaling molecule called PKC.

The finding that alpha-defensin-1 acts on both the virus and the cell offers insights into the function of alpha-defensin-1 in innate immunity against HIV. In addition, this study provides a basis to develop defensin-like drugs for prevention of HIV and for therapeutic use in patients who are already infected.


'"/>

Source:JCI


Page: 1

Related biology news :

1. Defensins neutralize anthrax toxin
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/7/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... at the LEERINK Partners 6th Annual Global Healthcare Conference ... February 15, 2017 at 10 a.m. Eastern Time. ... be accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast will ... Biomet,s Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:2/3/2017)... 2017  Texas Biomedical Research Institute announced that its Board ... as the Institute,s new President and CEO. Dr. Schlesinger ... 2017. He is currently the Chair of the Department of ... Microbial Interface Biology at Ohio State University. "We ... and CEO of Texas Biomed," said Dr. James O. ...
(Date:2/2/2017)... 2017  EyeLock LLC, a market leader of iris-based ... " What You Should Know About Biometrics in the ... authenticity is a growing concern. In traditional schemes, cryptography ... traditional authentication schemes such as username/password suffer from inherent ... offers an elegant solution to the problem of high-security ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... , ... February 24, 2017 , ... ... procedures can be safely completed in an ambulatory surgery center (ASC) with satisfactory ... procedures and previous two-year TDR studies. , Jake Lubinski, president of AxioMed, ...
(Date:2/24/2017)... , Feb. 24, 2017  Aethlon Medical, Inc. ... note authored by its Chairman and CEO, Jim ... the Munich Security Conference last Saturday, Bill Gates ... could kill more people than nuclear weapons. Mr. Gates ... and U.K. intelligence agencies, that scientific terrorists have access ...
(Date:2/24/2017)... , ... February 24, 2017 , ... FireflySci, Inc is ... in late 2014, FireflySci had the goal of bringing their powerful cuvette ... to shape the path that FireflySci is going on as they add yet another ...
(Date:2/23/2017)... and NEW YORK , Feb. ... Lumeon , a leading digital health company, and ... provider of telemedicine and remote patient monitoring, announce ... telemedicine reimbursements.  DN Telehealth maximizes ... in real-time, extending consultations beyond a physical clinical ...
Breaking Biology Technology: